BMS Korea keeps top spot in chronic hepatitis B market

Published: 2013-05-21 07:00:00

Updated: 2013-05-21 07:00:00

BMS Korea, a Korean unit of Bristol Myers Squibb Company, maintained its dominant position in the domestic chronic hepatitis B market during the January-April period of the year, although its competitor Gilead Sciences is slowly expanding market share, industry data showed recently.

According ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK